Table 1. Baseline characteristics.
| Octogenarians, n = 261 | Non-octogenarians, n = 483 | P-value | |
| Data provided as n (%) or mean ± SD. ASA: acetylsalicylic acid; CABG: coronary artery bypass grafting; LAAC: left atrial appendage closure; PCI: percutaneous coronary intervention. | |||
| Age at time of LAAC, yrs | 84.0 ± 3.0 | 70.4 ± 7.8 | < 0.0001 |
| Body mass index, kg/m2 | 26.9 ± 4.6 | 29.6 ± 18.9 | 0.035 |
| Female gender | 123 (47.1%) | 153 (31.7%) | < 0.0001 |
| Arterial hypertension | 236 (90.4%) | 434 (89.9%) | 0.81 |
| Diabetes mellitus | 80 (30.7%) | 159 (32.9%) | 0.53 |
| Coronary artery disease | 158 (60.5%) | 236 (48.9%) | 0.002 |
| Prior PCI/CAGB | 136 (52.1%) | 215 (44.5%) | 0.047 |
| Left ventricular ejection fraction | 54.2% ± 12.6% | 54.0% ± 12.3% | 0.78 |
| Congestive heart failure | 91 (34.9%) | 151 (31.3%) | 0.32 |
| GFR, mL/min | 59.5 ± 24.7 | 69.6 ± 28.1 | 0.13 |
| Prior all-cause stroke | 68 (26.1%) | 156 (32.3%) | 0.067 |
| Prior major bleeding | 161 (61.7%) | 269 (55.7%) | 0.11 |
| CHA2DS2-VASc score | 5.2 ± 1.2 | 4.3 ± 1.7 | < 0.0001 |
| HAS-BLED score | 3.3 ± 0.8 | 3.1 ± 1.1 | 0.001 |
| Anti-thrombotic medical therapy prior to LAAC | |||
| Any oral anticoagulation | 175 (67.0%) | 317 (65.6%) | 0.65 |
| Vitamin K antagonists | 124 (47.5%) | 227 (47.0%) | 0.86 |
| Non-vitamin K dependent oral antiocoagulants | 55 (21.1%) | 97 (20.1%) | 0.75 |
| ASA | 94 (36.0%) | 175 (36.2%) | 0.95 |
| Platelet inhibitors other than ASA | 46 (17.6%) | 87 (18.0%) | 0.90 |